Trends in Industry Payments to Physicians for Antihyperglycemic Therapies Between 2014 and 2018

J Gen Intern Med. 2021 Aug;36(8):2492-2494. doi: 10.1007/s11606-020-06215-0. Epub 2020 Sep 18.

Authors

Kosuke Inoue¹, O Kenrik Duru², Carol M Mangione^{2

3}, Yusuke Tsugawa^{2

3}

Affiliations

¹ Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, 90095, USA. koinoue@ucla.edu.
² Medicine & Health Policy and Management, Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90024, USA.
³ Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, CA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Conflict of Interest
Drug Industry
Humans
Hypoglycemic Agents*
Industry
Physicians*
United States

Substances

Hypoglycemic Agents

Grants and funding